← Leaderboards
Arnold Louie
University Of Florida
$12,883,478
Attributed
$20,965,344
Total exposure
8
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $4.1M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$35,292,535 · 10
By mechanism
P01$19,128,802 · 5
R01$15,088,701 · 4
R56$1,075,032 · 1
Top collaborators
- George Louis Drusano22 shared
- Ashley Brown1 shared
- Jurgen Bernd Bulitta1 shared
- Michael N. Neely1 shared
Most similar at University Of Florida
Same institution · by research overlap
- George Louis Drusano$18,475,919
- Michael N. Neely$9,304,264
- Yinzhi Lang$1,261,878
- Ashley Brown$2,797,681
- Justin Ray Kaspar$935,340
Others in their field
Top investigators on “Resistance”
- Judith S. Currier · University Of California Los Angeles$243,611,225
- Gregory H Reaman · National Childhood Cancer Foundation$217,720,574
- Joseph J. Eron · Univ Of North Carolina Chapel Hill$180,092,958
- Ralph Parchment · Leidos Biomedical Research, Inc.$149,556,948
- Wafaa M. El-Sadr · Columbia University Health Sciences$113,991,858
- Peter C Adamson · National Childhood Cancer Foundation$113,790,601
Research focus
ResistancePharmaceutical PreparationsFiberMathematical ModelMouse ModelDoseInfectionRegimenIn VitroIn VivoOrganismDosagePathogenCombined Modality TherapyDrug CombinationsValidationDrug KineticsPreventAntibioticsAnimalsBaseKillingsPharmacodynamicsBacteria
Grant awards (36)
Translational development of new agents alone and in combination to combat Gram-negative pathogens important in Ventilator- Associated Bacterial Pneumonia: Leveraging the Gram-negative toolbox that is$2,339,559
P01 · FY2025 · AI · contact PI
Optimizing Multi-drug Mycobacterium tuberculosis Therapy for Rapid Sterilization and Resistance Suppression$1,324,774
R01 · FY2025 · AI · contact PI
Building and prospective validation of promising mono- and combination regimens that optimize killing of CRAB and CR-Klebsiella pneumoniae and for resistance suppression in murine pneumonia models$159,126
P01 · FY2025 · AI · contact PI
Optimizing Multi-drug Mycobacterium tuberculosis Therapy for Rapid Sterilization and Resistance Suppression$1,403,884
R01 · FY2024 · AI
Building and prospective validation of promising mono- and combination regimens that optimize killing of CRAB and CR-Klebsiella pneumoniae and for resistance suppression in murine pneumonia models$152,378
P01 · FY2024 · AI · contact PI
Optimizing Multi-drug Mycobacterium tuberculosis Therapy for Rapid Sterilization and Resistance Suppression$1,314,301
R01 · FY2023 · AI
Optimizing Combination Therapy to Accelerate Clinical Cure of Tuberculosis$2,619,058
P01 · FY2020 · AI
Rapid Identification of Optimal Combination Regimens for Pseudomonas aeruginosa$687,939
R01 · FY2020 · AI
Novel Murine Studies for Optimizing Effective Short-Course TB Therapy$562,357
P01 · FY2020 · AI · contact PI
Optimizing Combination Therapy to Accelerate Clinical Cure of Tuberculosis$2,710,457
P01 · FY2019 · AI
Rapid Identification of Optimal Combination Regimens for Pseudomonas aeruginosa$932,445
R01 · FY2019 · AI
Novel Murine Studies for Optimizing Effective Short-Course TB Therapy$458,642
P01 · FY2019 · AI · contact PI
Optimizing Combination Therapy to Accelerate Clinical Cure of Tuberculosis$2,332,983
P01 · FY2018 · AI
Rapid Identification of Optimal Combination Regimens for Pseudomonas aeruginosa$1,007,027
R01 · FY2018 · AI
Novel Murine Studies for Optimizing Effective Short-Course TB Therapy$458,510
P01 · FY2018 · AI · contact PI
Optimizing Combination Therapy to Accelerate Clinical Cure of Tuberculosis$1,988,816
P01 · FY2017 · AI
Rapid Identification of Optimal Combination Regimens for Pseudomonas aeruginosa$729,901
R01 · FY2017 · AI
Novel Murine Studies for Optimizing Effective Short-Course TB Therapy$313,356
P01 · FY2017 · AI · contact PI
Optimizing Combination Therapy to Accelerate Clinical Cure of Tuberculosis$2,336,318
P01 · FY2016 · AI
Rapid Identification of Optimal Combination Regimens for Pseudomonas aeruginosa$751,274
R01 · FY2016 · AI
Novel Murine Studies for Optimizing Effective Short-Course TB Therapy$599,656
P01 · FY2016 · AI · contact PI
Combination Therapy Modeling for M tuberculosis Resistance Suppression and Kill$1,075,032
R56 · FY2014 · AI · contact PI
Optimization of Neoglycoside Antibiotics for Nosocomial Pathogens and Select Agen$724,489
R01 · FY2014 · AI
Optimization of Neoglycoside Antibiotics for Nosocomial Pathogens and Select Agen$657,363
R01 · FY2013 · AI
Optimization of Neoglycoside Antibiotics for Nosocomial Pathogens and Select Agen$687,841
R01 · FY2012 · AI
Optimization of Neoglycoside Antibiotics for Nosocomial Pathogens and Select Agen$1,044,441
R01 · FY2011 · AI
Resistance Suppression for P. Aeruginosa using Novel Combination Therapy Modeling$626,816
R01 · FY2011 · AI
Optimization of Neoglycoside Antibiotics for Nosocomial Pathogens and Select Agen$874,998
R01 · FY2010 · AI
Resistance Suppression for P. Aeruginosa using Novel Combination Therapy Modeling$750,762
R01 · FY2010 · AI
Resistance Suppression for P. Aeruginosa using Novel Combination Therapy Modeling$782,530
R01 · FY2009 · AI
Yersinia Pestis$475,930
P01 · FY2009 · AI · contact PI
Resistance Suppression for P. Aeruginosa using Novel Combination Therapy Modeling$787,916
R01 · FY2008 · AI
Yersinia Pestis$482,718
P01 · FY2008 · AI · contact PI
Yersinia Pestis$417,348
P01 · FY2007 · AI · contact PI
Yersinia Pestis$377,622
P01 · FY2006 · AI · contact PI
Yersinia Pestis$343,968
P01 · FY2005 · AI